8-K: TransCode's TTX-MC138 Shows Promise in Glioblastoma

TransCode Therapeutics announced preclinical data supporting its lead candidate TTX-MC138 for glioblastoma treatment, showing extended survival in models.

Summary

• Preclinical research on TTX-MC138 for glioblastoma multiforme (GBM) was published in the peer-reviewed Journal of Functional Biomaterials (Volume 17, Issue 1).
• The study, titled 'Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma Models,' resulted from a collaboration with Michigan State University.
• TTX-MC138 was successfully delivered to human GBM tumors implanted in murine models following intravenous injection.
• The treatment demonstrated sustained target engagement within the tumor and suppression of miR-10b, a microRNA highly expressed in GBM cells that drives tumor survival and invasiveness.
• TTX-MC138 induced apoptotic activity in tumors by five-fold, consistent with observed tumor cell death.
• Treatment with TTX-MC138 resulted in a statistically significant increase in survival in aggressive glioblastoma models.
• Existing investigational new drug (IND) enabling studies, pharmacokinetics, biodistribution, and required toxicity studies for TTX-MC138 have been completed.
• The formulation has shown appreciable safety in Phase 1 clinical trials in patients with non-central nervous system (CNS) cancers.
• These results support advancing TTX-MC138 to future clinical evaluation in patients with GBM.

Sentiment

Score: 8

Explanation: The preclinical data for TTX-MC138 in glioblastoma shows significant promise, demonstrating statistically significant survival benefits in aggressive models and successful systemic delivery to brain tumors. Coupled with existing safety data, this represents a strong positive step towards addressing a high unmet medical need.

Positives

• Successful systemic delivery of TTX-MC138 to brain neoplasms in murine models, overcoming key delivery barriers.
• Demonstrated sustained target engagement within tumors and suppression of the miR-10b target.
• Induced a five-fold increase in apoptotic activity in tumors, indicating significant tumor cell death.
• Achieved a statistically significant increase in survival in aggressive glioblastoma models.
• Existing IND-enabling studies and Phase 1 safety data in non-CNS cancers provide a strong foundation for rapid clinical advancement in GBM.
• Broadens the potential reach of RNA-based therapeutics beyond metastatic solid tumors.

Risks

• Risks associated with drug discovery and development.
• The risk that results of clinical trials will not be consistent with preclinical studies or expectations.
• Risks associated with the conduct of clinical trials.
• Risks associated with the company's financial condition and its need to obtain additional funding to support business activities, including its ability to continue as a going concern.
• Risks associated with the timing and outcome of planned regulatory submissions.
• Risks associated with obtaining, maintaining, and protecting intellectual property.
• Risks associated with the company's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties.
• Risks of competition from other companies developing products for similar uses.
• Risks associated with the company's dependence on third parties.
• Risks associated with geopolitical events and pandemics, including the COVID-19 coronavirus and military actions.

Future Outlook

TransCode Therapeutics anticipates advancing TTX-MC138 to future clinical evaluation in patients with glioblastoma multiforme (GBM). A Phase 2a clinical trial for metastatic disease is anticipated to begin in the first half of 2026. The company aims to broaden the potential reach of its RNA-based therapeutics beyond metastatic solid tumors.

Management Comments

• "This research represents an important step forward in targeting one of the most treatment-resistant forms of cancer." Dr. Zdravka Medarova, CSO of TransCode.
• "By pairing our differentiated delivery approach with robust biological support, we are broadening the potential reach of our RNA-based therapeutics beyond metastatic solid tumors." Dr. Zdravka Medarova, CSO of TransCode.

Industry Context

Glioblastoma is recognized as the most aggressive primary brain cancer, with a median survival typically under two years despite current standard-of-care interventions. The molecular target of TTX-MC138, microRNA-10b (miR-10b), is a critical driver of tumor survival, growth, and invasiveness in GBM cells. The successful systemic delivery of antisense oligonucleotides (ASOs) to brain neoplasms, overcoming challenges like nucleic acid degradation and limited tumor penetration, represents a significant potential breakthrough in a field with high unmet medical need and substantial delivery barriers.

Stakeholder Impact

• Shareholders: Potential for increased company valuation due to positive preclinical data and expansion of the lead candidate's therapeutic scope into a high-need indication.
• Patients (Glioblastoma): Offers significant hope for a novel and effective treatment option for a highly aggressive and currently underserved cancer.
• Medical Community: Provides new scientific insights and a promising therapeutic candidate for glioblastoma research and treatment.
• Employees: Positive research outcomes can boost morale and validate the company's scientific and development efforts.

Next Steps

• Advance TTX-MC138 to future clinical evaluation in patients with glioblastoma multiforme (GBM).
• Anticipate beginning a Phase 2a clinical trial for metastatic disease in the first half of 2026.

Key Dates

Recommendation

The announcement details highly promising preclinical results for TTX-MC138 in glioblastoma, a notoriously difficult-to-treat cancer with high unmet medical need. The statistically significant survival benefit in aggressive models, coupled with existing IND-enabling studies and Phase 1 safety data, significantly de-risks the program's progression to human clinical trials for GBM. This expands the potential market for TTX-MC138 beyond its current metastatic disease focus and represents a substantial value driver for the company. The anticipated Phase 2a trial in H1 2026 further underscores the near-term catalysts.

Keywords

Glioblastoma, GBM, TTX-MC138, RNA therapeutics, microRNA-10b, miR-10b, Preclinical data, Cancer treatment, Oncology, Brain cancer, TransCode Therapeutics